There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
N Engl J Med 2011;365:883–91. Atrial fibrillation (AF) significantly increases the risk of thromboembolism. Until recently, thromboprophylaxis in high-risk AF patients has been limited to vitamin K antagonists. Emerging, novel oral anticoagulants are...
Thank you for becoming a member of KMOV.com. You now have full access to the best local coverage and late breaking news from KMOV.com. Soon you will be redirected to the page you were seeking, and a confirmation email will be delivered to you. KMOV.com...
This product image provided by Janssen Pharmaceuticals Inc. , shows a bottle of Xarelto 20mg. Xarelto, known chemically as rivaroxaban, was approved eight weeks ago for use in patients who have an irregular heartbeat called atrial fibrillation not... View Photo »
There are now new oral anticoagulants on the market, which are at least as safe and effective as compared with warfarin, and they do not require regular coagulation monitoring. So many patients with atrial fibrillation will switch from warfarin to the new substances in the very near future
For years, the lower incidence of AF in African Americans was thought to be due to racial disparities in health care, but research is pointing toward genetics as the cause for the apparent paradox, said Dawood Darbar, director of the Atrial...
Stroke-related language impairment adds about $1,703 per patient to medical costs the first year after stroke, according to research reported in Stroke: Journal of the American Heart Association.
Atrial fibrillation is growing in prevelance. Up to 12 million Americans will have the condition by 2050. While not life-threatening, atrial fibrillation is a leading cause of stroke among people 65 years and older. Recommend this story on Facebook,...
Singer Barry Manilow, who is an atrial fibrillation (AFib) patient, explains how it feels to have AFib during a briefing advocating education about the disease, Thursday, Sept. 15, 2011, during a news conference on Capitol Hill in Washington. View Photo »
These conditions include atrial fibrillation, treatment of deep-vein thrombosis and patients with artificial heart valves.
Patients typically experience rapid heartbeats that can lead to debilitating fatigue, dizziness, fainting or shortness of breath if left untreated. Atrial fibrillation has a devastating impact on more than 2.7 million Americans, yet for many patients...
The views expressed here do not constitute medical advice, and do not represent the position of Johns Hopkins Medicine or Remedy Health Media, LLC, which has no responsibility for any comments posted on this site. Atrial Fibrillation (AF) can be a...
Atrial fibrillation (AF or afib) is a cardiac arrhythmia (abnormal heart rhythm) that involves the two upper chambers (atria) of the heart. It can often be identified by taking a pulse and observing that the heart beats don't occur at regular intervals, but a conclusive indication of AF is the absence of P waves on an electrocardiogram (ECG). AF... Full Article
This product image provided by Janssen Pharmaceuticals Inc. , shows a bottle of Xarelto 20mg. Xarelto, known chemically as rivaroxaban, was approved eight weeks ago for use in patients who have an irregular heartbeat called atrial fibrillation not caused by a heart valve problem. More...
View Photo »This product image provided by Janssen Pharmaceuticals Inc. , shows a bottle of Xarelto 20mg. Xarelto, known chemically as rivaroxaban, was approved eight weeks ago for use in patients who have an irregular heartbeat called atrial fibrillation not caused by a heart valve problem. More...
View Photo »There are now new oral anticoagulants on the market, which are at least as safe and effective as compared with warfarin, and they do not require regular coagulation monitoring. So many patients with atrial fibrillation will switch from warfarin to the new substances in the very near future
These conditions include atrial fibrillation, treatment of deep-vein thrombosis and patients with artificial heart valves.
Continuous atrial diagnostics conducted by the BIOTRONIK Home Monitoring® technology give us an opportunity to assess the frequency and duration of atrial fibrillation (AF) episodes defined as AHRE.
The decision by the jury underlines the outstanding innovation Pradaxa® brings for patients and doctors, providing a much needed advance in stroke prevention in atrial fibrillation, an area of high therapeutic need.
